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Abstract 
Approximately one-third of people with epilepsy receive insufficient benefit from currently available 
anticonvulsant medication, and some evidence suggests that this may be due to a lack of effective 
penetration into brain parenchyma. The current study investigated the ability of biodegradable polymer 
implants loaded with levetiracetam to ameliorate seizures following implantation above the motor cortex 
in the tetanus toxin model of temporal lobe epilepsy in rats. The implants led to significantly shorter 
seizures and a trend towards fewer seizures for up to 1 week. The results of this study indicate that drug-
eluting polymer implants represent a promising evolving treatment option for intractable epilepsy. Future 
research is warranted to investigate issues of device longevity and implantation site. 
Keywords 
tetanus, levetiracetam, toxin, model, temporal, lobe, epilepsy, rats, loaded, polymer, implants, 
biodegradable 
Disciplines 
Engineering | Physical Sciences and Mathematics 
Publication Details 
Halliday, A. J., Campbell, T. E., Nelson, T. S., McLean, K. J., Wallace, G. G. & Cook, M. J. (2013). 
Levetiracetam-loaded biodegradable polymer implants in the tetanus toxin model of temporal lobe 
epilepsy in rats. Journal of Clinical Neuroscience, 20 (1), 148-152. 
Authors 
Amy J. Halliday, Toni E. Campbell, Timothy S. Nelson, Karen J. McLean, Gordon G. Wallace, and Mark J. 
Cook 
This journal article is available at Research Online: https://ro.uow.edu.au/aiimpapers/506 
Halliday   1 
 
Title page 
 
Title: 
Levetiracetam-loaded biodegradable polymer cortical implants in the tetanus toxin model of 
temporal lobe epilepsy. 
 
Authors: 
Amy J. Halliday1, 3 
Toni E. Campbell 3 
Timothy S. Nelson2 
Karen J. McLean1 
Gordon G. Wallace 3 
Mark J. Cook1, 2 
 
Affiliations: 
1 Centre for Clinical Neurosciences and Neurological Research, St Vincent’s Hospital 
Melbourne, PO Box 2900, Fitzroy, Victoria, Australia 3065 
2 The Bionic Ear Institute, 384-388 Albert St, East Melbourne, Victoria, Australia 3002 
3 Intelligent Polymer Research Institute and ARC Centre of Excellence for Electromaterials 
Science, AIIM Facility, Innovation Campus, University of Wollongong, Wollongong, New 
South Wales, Australia 2522 
 
Corresponding author: 
Amy Halliday 
 
Centre for Clinical Neurosciences and Neurological Research 
5th Floor, Daly Wing 
St Vincent’s Hospital 
35 Victoria Pde 
Fitzroy VIC 3065 
Australia 
 
Telephone: +61 4 2988 5776  
Fax: +61 3 9288 3350 
email: amyjhalliday@gmail.com 
 
Sources of support 
• the Victorian Government’s Science Technology and Innovation Initiative 
administered by the Department of Industry, Innovation and Regional Development 
•  the Victorian Government through its Operational Infrastructure Support Program 
and the Helen Macpherson Smith Trust, to the Bionic Ear Institute 
 
Halliday   2 
 
Abstract 
Approximately one third of people with epilepsy receive insufficient benefit from currently 
available anticonvulsant medication, and some evidence suggests that this may be due to a 
lack of effective penetration into brain parenchyma. The current study investigated the ability 
of biodegradable polymer implants loaded with Levetiracetam to ameliorate seizures 
following implantation above the motor cortex in the tetanus toxin model of temporal lobe 
epilepsy in rats. The implants led to significantly shorter seizures and a trend towards fewer 
seizures for up to one week. The results of this study indicate that drug-eluting polymer 
implants represent a promising evolving treatment option for intractable epilepsy. Future 
research is warranted to investigate issues of device longevity and implantation site. 
Key words 
Polymer, levetiracetam, epilepsy, anticonvulsant, tetanus toxin, biodegradable, drug delivery, 
implantable devices. 
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1 Introduction 
Epilepsy is among the most common chronic neurological disorders, affecting nearly 1% of 
the population. Epilepsy is well recognised for being highly refractory to medical treatment, 
with up to one third of patients receiving no benefit from anticonvulsant medication.  
 
A range of treatment options are currently being investigated aimed at improving the 
availability of anticonvulsant drugs to the brain. One such treatment option is the intracranial 
implantation of polymer-based drug delivery systems. These implants are made of materials 
that slowly break down following implantation, gradually releasing their drug load into the 
implant site. Recent studies have demonstrated some success at using similar 
biodegradable implants to treat animal models of several neurological disorders with focal 
pathologies such as Parkinson’s disease, Huntington’s disease and Alzheimer’s disease[1]; 
however, their application to animal models of epilepsy have to date been less successful.  
 
The most intensely investigated biodegradable polymer in intracranial drug delivery for 
neurological disorders has been the copolymer poly-lactide-co-glycolide (PLGA). PLGA-
based implants have been shown to be very well tolerated by the brain in animal models of 
neurological disorders[2-7]. Given their biocompatibility and success in animal models of other 
focal neurological disorders, we sought to investigate the efficacy of PLGA sheets loaded 
with the novel anticonvulsant drug Levetiracetam (LEV) in an animal model of epilepsy. In 
this investigation, sheets of PLGA loaded with LEV were developed and their ability to 
ameliorate seizures was investigated in the hippocampal tetanus toxin model of mesial 
temporal lobe epilepsy (TLE) in rats. 
2 Methods 
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2.1 Animals 
Adult male Sprague-Dawley rats were obtained from FlindersUniversity (Adelaide, SA, 
Australia) and housed individually in 12 h light/dark cycles with ad libitum access to food and 
water. All experiments were approved by St Vincent’s Hospital (Melbourne) Animal Ethics 
Committee and conducted in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (2004). 
2.2 Polymer production 
Polymer sheets were produced by pipetting 1 mL of a solution of PLGA 85:15 (2% w/v; 
SigmaAldrich, Australia) and LEV (4% w/v; gift from UCB Pharma, Belgium) in 
dichloromethane (SigmaAldrich, Australia) into a Teflon mold. The solvent was evaporated 
overnight, resulting in a 2 cm2 film with a theoretical LEV loading of 67% w/w. The sheets 
were cut to size (4mm x 2mm) immediately before implantation.  
2.3 In vitro drug release 
Discs of 2.5 mm diameter were cut from the LEV films, placed in vials of 350 µL of artificial 
cerebrospinal fluid (aCSF) and incubated in a water bath at 37C. At set time points, three 
vials were removed from the water bath and the concentration of LEV in the sample 
determined using high performance liquid chromatography (HPLC). 
Artificial cerebral spinal fluid contained sodium chloride (NaCl; 0.866% w/v), potassium 
chloride (KCl; 0.224% w/v), calcium dichloride (CaCl2.2H2O; 0.0206% w/v) and magnesium 
dichloride (MgCl2.6H2O; 0.0164% w/v) in 1 mM phosphate buffer (pH 7.4).  
2.4 Implantation surgery 
Two days prior to surgery, rats were administered oral antibiotics to assist in the prevention 
of infection following surgery (Baytril, 3.5mL/L in drinking water). Immediately prior to 
surgery, rats were anaesthetized with an i.p. injection of ketamine (70 mg/kg) and xylazine 
(10 mg/kg), and administered Carprofen (5 mg/kg, s.c.) for pain relief. Once anaesthetized, 
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rats were placed in a stereotaxic apparatus, and administered isoflurane (0.5% in oxygen, 2 
L/min) via a nose-cone. 50 ng of tetanus toxin in 0.5 µL of phosphate-buffered saline was 
injected into the right hippocampus (AP: -3.5 mm; ML: + 3.0 mm; DV: -3.5 mm from Bregma) 
via a microsyringe at a rate of 1 µL/min. The syringe was left in place for 5 min before being 
slowly retracted. A craniotomy was created over the left motor and somatosensory cortices 
(5 mm x 3 mm, centred over AP: 0 mm, ML: -4.0 mm from Bregma) and a 16 channel 
microwire array electrode was implanted within the motor cortex (Tucker-Davis Technologies 
(TDT), USA). A second craniotomy was created above the right motor cortex (5 mm x 5 mm, 
centered over AP: 0 mm, ML: +4.0 mm from Bregma), the central section of bone removed 
and a flap cut in the exposed dura. A sheet of polymer was placed on the exposed brain, 
and the dural flap and bone piece replaced. Control rats received a craniotomy without 
implantation of a polymer (n=10) while experimental rats received polymers containing LEV 
(n=11). The polymer craniotomy site was sealed with an alginate-based hydrogel and the 
entire surgical site covered with dental cement and sutured closed. The animal was placed 
on a heat pad for recovery. 
2.5 EEG monitoring 
Beginning three days after surgery, rats were monitored for at least two hours on at least 
three days per week for three weeks following surgery. Rats were anaesthetised with 
isoflurane (4% in oxygen, 2 L/min), and a shielded cable was used to connect the electrode 
to the electroencephalogram (EEG) acquisition system, which consisted of TDT processors 
and high impedance head stages driven by custom-designed software. The rat was allowed 
to recover fully from the anesthetic before recording began so that EEGs were obtained from 
freely moving rats. 
2.6 Data analysis 
ECoGs were visualized using a custom-designed MATLAB programme, and used to 
determine the duration of each seizure (seconds) and seizure frequency (seizures/hour). 
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Seizure severity was calculated by dividing number of convulsive seizures by the total 
number of seizures (convulsive proportion). 
The mean seizure duration was calculated for five recording blocks, each being four days of 
duration. Days included in each block were as follows: block one: days three to six; block 
two: days seven to ten; block three: days 11 to 14; block four: days 15 to 18; and block five: 
days 19 to 21. The mean seizure duration for each block was calculated by (a) first 
averaging the duration of all seizures that a rat had in a single recording session, (b) then 
averaging all that rat’s session means over the block, and (c) determining the mean ± the 
standard error of the mean (SEM) of the block averages from all rats. This was done to 
eliminate any bias from rats that had more frequent seizures or that were monitored more 
frequently.  
The mean seizure frequency was also calculated for each of the recording blocks. This was 
calculated by (a) first determining the seizure frequency of each recording session, (b) 
averaging all the seizure frequencies across the block for each rat, and (c) determining the 
mean ± SEM of the seizure frequency averages from all rats.  
Seizure severity was also determined for each recording block, using the observations 
recorded during ECoG monitoring. Seizure severity was calculated by (a) first dividing 
number of convulsive seizures by the total number of seizures to give the proportion of 
seizures that were convulsive (convulsive proportion) for each recording session, (b) 
averaging all the convulsive proportions across the block for each rat, and (c) determining 
the mean ± SEM of the convulsive proportions from all rats.  
The difference in the median seizure duration and frequency between implanted and 
unimplanted control rats was determined for each block using a Wilcoxon-Mann-Whitney 
two-sample rank-sum test, performed using SigmaStat (v11.0, Systat Software, San Jose, 
CL, USA). 
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3 Results 
3.1 In vitro drug release 
The total quantity of LEV released from the disk in each sample was determined using 
HPLC, and the mean and standard deviation calculated for each time point (Fig. 1). These 
results demonstrate that majority of drug release from the films is complete by day three, 
afterwhich point the drug release appeared to reach a plateau. Due to the large quantity of 
drug encapsulated, sensitive measurement techniques, small variations in disk size and 
potential evaporation of aCSF from the vials over time, there was a high degree in variation 
in the results. 
3.2 Electrocorticography 
Injection of tetanus toxin into the hippocampus resulted in a syndrome of spontaneous 
seizures resembling those seen in human temporal lobe epilepsy[8, 9]. Rats began to exhibit 
spontaneous seizures 2-13 days following tetanus toxin injection. Seizures consisted of 
either non-convulsive episodes of behavioral arrest, staring and chewing, or convulsive 
events that progressed through behavioral arrest, facial clonus, bilateral forelimb clonus, 
rearing and falling. These clinical events correlated with epileptiform discharges on the 
ECoG that consisted of an initial phase of high frequency polyspike activity of increasing 
amplitude followed by a period of lower amplitude rhythmic spike and wave activity (see Fig. 
2). The duration of each seizure was measured using the ECoG and was defined as the time 
(in seconds) from the beginning of polyspike activity to the termination of spike and wave 
activity prior to the post-ictal depression. 
3.3 Seizure duration 
Rats implanted with LEV-loaded sheets had significantly shorter seizures compared to 
control rats during block one (p = 0.024). Control rats had long seizures at the onset of the 
seizure syndrome and progressed to shorter seizures from day 7 onwards, whereas rats 
Halliday   8 
 
implanted with LEV sheets did not manifest longer seizures at the start of the seizure 
syndrome (Figure 3A).  
3.4 Seizure frequency 
Implanted rats did not have significantly fewer seizures than control rats at any time point. 
There was a trend towards fewer seizures in LEV-implanted rats during block one, however 
this difference was not significant (p = 0.078) (Figure 3B).  
3.5 Seizure severity 
All rats exhibited mostly non-convulsive seizures during the first days after tetanus toxin 
injection. One week after tetanus toxin injection, control rats rapidly progressed to exhibiting 
almost exclusively convulsive seizures whilst, in contrast, rats implanted with LEV-loaded 
sheets continued to have predominantly non-convulsive events, however this difference did 
not reach significance (proportion of seizures that were convulsive: control = 0.966 ± 0.0218; 
implanted = 0.470 ± 0.145; p = 0.086, Fig. 3C). By the third monitoring block, seizures 
exhibited by control rats had settled and about half of the events were non-convulsive, 
similar to those exhibited by implanted rats during this block. This pattern continued until the 
end of monitoring at three weeks post-injection. 
4 Discussion 
Biodegradable polymer sheets containing a large amount of LEV were implanted above the 
motor and somatosensory cortices of epileptic rats with a hippocampal seizure focus. 
Implantation of the sheets led to shorter seizures and a trend towards fewer and less severe 
seizures in the first week after implantation compared to rats that did not receive the implant.  
 
An important limitation of the current study is that a single group of control animals were 
investigated. These animals received an injection of tetanus toxin and a sham craniotomy, 
without the implantation of a polymer sheet. It is possible that the presence of the polymer 
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sheet, irrespective of drug release, may have altered the function of the underlying brain or 
otherwise affected the intracranial environment such that seizures were ameliorated. An 
additional control group implanted with blank polymers, created in the same manner but with 
the drug load excluded or replaced with an inert sham substance, would assist in answering 
this question.  
 
There are several possible explanations for the limited efficacy of the implants in this study. 
Firstly, the implants used in this investigation had a very high theoretical LEV load of 67% 
w/w.Our in vitro study demonstrated that such high drug loadings limited the ability of the 
polymer to regulate the release of LEV into the surrounding environment, producing large 
quantities of drug release for a short time period after implantation. This may explain why the 
implants produced a brief effect immediately after implantation. 
 
Secondly, the sheets were implanted above the motor/somatosensory cortex whilst the 
seizure focus was within the hippocampus. In rats this distance is 4-5 mm. Previous 
investigations have shown that substances released from intraparenchymally implanted 
polymers are able to penetrate around 3 mm[10-14], suggesting that LEV released from the 
implants in our study would not have reached the seizure focus in the hippocampus in high 
concentrations. High concentrations of LEV in the motor and somatosensory cortices may 
have been able to slow or interrupt seizure propagation, leading to the observed reduction in 
seizure duration; however, the inadequate concentration in the hippocampus would have 
had no effect on seizure initiation and therefore on seizure frequency. 
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This study demonstrates the ability of polymer-based brain implants to reduce the impact of 
seizures in the tetanus toxin model of mesial TLE. Whilst the results are modest, their 
limitations can be explained by the construction and location of the polymer. Indeed, the 
evidence of a trend towards a reduction in seizure frequency is promising given the distance 
of the implant from the seizure focus. The results indicate that further investigations into the 
use of biodegradable polymer-based implants for epilepsy are warranted. The incorporation 
of more potent anticonvulsants will permit the production of an implant with longer-term drug 
release without sacrificing efficacy, and should extend the success seen in the period 
immediately post-implantation. Additionally, implantation of the polymer at the seizure focus 
may reduce seizure frequency, including injectable polymer formulationssuch as 
microspheres.  
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Captions 
Figure 1. In vitro LEV release from biodegradable PLGA films. 
 
Figure 2. Typical electrocorticograms recorded from tetanus-toxin injected rats during 
spontaneous seizures. 
 
Figure 3.Efficacy of LEV-loaded polymer sheets in tetanus toxin rats. The figures illustrate 
the mean (± SEM) of the seizure duration, frequency and severity in tetanus toxin injected 
rats with and without LEV-loaded implants. 
 
